Acquisitions - Narrative (Details) - USD ($)			1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 01, 2025	Apr. 01, 2025	Nov. 30, 2024	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2025	Dec. 31, 2024	Mar. 31, 2024
BioCenturion
Business Combination [Line Items]
Non-controlling interest related to variable interest entity							$ 4,100,000
Ownership interest in variable interest entity					50.00%
EyeLock | BioCenturion Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture		50.00%
PAC | Onkyo Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture		77.20%
Voting interest percentage in joint venture		85.10%
Sharp | Onkyo Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture		22.80%
Voting interest percentage in joint venture		14.90%
GalvanEyes | BioCenturion Joint Venture
Business Combination [Line Items]
Ownership percentage in joint venture			50.00%
VOXX
Business Combination [Line Items]
Shares of investment held (in shares)					6,463,808		6,463,808
Non-controlling ownership interest								29.00%
BioCenturion
Business Combination [Line Items]
Non-controlling ownership interest					50.00%
VOXX
Business Combination [Line Items]
Purchase price per share (in dollars per share)		$ 7.5
Cash consideration paid		$ 148,256,998
Fair value of previously held investment in VOXX		48,478,560			$ 48,500,000
Net sales/revenue attributable to acquiree				$ 78,800,000		$ 78,800,000
Net income (loss) attributable to acquiree				(4,000,000)		(4,000,000)
Acquisition costs incurred				2,300,000		3,100,000
GalvanEyes
Business Combination [Line Items]
Cash consideration paid			$ 2,900,000
Net sales/revenue attributable to acquiree				200,000		1,100,000
Net income (loss) attributable to acquiree				(600,000)		(1,800,000)
Earn out provision period			15 years
Total earn out, maximum potential payment			$ 15,000,000
Current value of earn out			$ 1,500,000
BioCenturion
Business Combination [Line Items]
Cash consideration paid		$ 4,100,000
BioConnect
Business Combination [Line Items]
Acquisition costs incurred				$ 200,000		$ 200,000
BioConnect | Subsequent Event
Business Combination [Line Items]
Total transaction consideration, net	$ 12,500,000